|Packaging Size||1 X 34|
Glenmark Pharmaceuticals announced that it will introduce a 400 mg version of oral antiviral FabiFlu, for the treatment of mild to moderate COVID-19 in India. The company informs that the higher strength will improve patient compliance and experience, by effectively reducing the number of tablets that patients require per day.
The 200 mg dosage of FabiFlu required patients to take 18 tablets on Day 1 (nine in the morning and nine in the evening), followed by eight tablets each day thereafter for a maximum of 14 days. With the new 400 mg version, patients need to consume nine tablets on Day 1 (4.5 in the morning and 4.5 in the evening), and thereafter two tablets twice a day from Day 2 till the end of the course.